MUC1 Dendritic Cell Vaccine

Identification

Generic Name
MUC1 Dendritic Cell Vaccine
DrugBank Accession Number
DB05477
Background

Dendritic Cell (DC) Therapy is a newly emerging and potent form of immune therapy that amplifies the actions of the body's own immune system to help fight cancer, AIDS and other serious conditions. The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic cells not only activate lymphocytes to induce the immune response, but they also minimize autoimmune reactions by downplaying self-antigens to stimulated T-cells. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
Not Available

Pharmacology

Indication

Investigated for use/treatment in cancer/tumors (unspecified) and ovarian cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

The Dendritic Cell is an immune cell whose role is the recognition, processing and presentation of foreign antigens to the T-cells to initiate a primary response in the effector arm of the immune system. Dendritic Cell Therapy involves the harvesting of blood cells (ie monocytes or macrophages) from a patient and processing them in the laboratory to produce a greater than typical Dendritic Cell concentration. These cells are then given back to a patient as a vaccine in order to allow for a potent immune response to cancer.

Mechanism of action

Use of increased concentration of dendritic cells to amplify immune responses to cancer.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Cancer Vac / Cancer Vac Mannan-MUC1 / CVac

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Whiteside TL, Odoux C: Dendritic cell biology and cancer therapy. Cancer Immunol Immunother. 2004 Mar;53(3):240-8. Epub 2003 Dec 18. [Article]
  2. Conrad C, Nestle FO: Dendritic cell-based cancer therapy. Curr Opin Mol Ther. 2003 Aug;5(4):405-12. [Article]
  3. Vermorken JB, Van Tendeloo VF: Dendritic cell therapy of cancer: can it fulfill its promise? Expert Rev Anticancer Ther. 2003 Feb;3(1):1-3. [Article]
  4. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T, Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer. 2002 May 20;86(10):1529-33. [Article]
  5. Grolleau A, Sloan A, Mule JJ: Dendritic cell-based vaccines for cancer therapy. Cancer Treat Res. 2005;123:181-205. [Article]
PubChem Substance
347910162

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentAstrocytoma, Grade IV / Brain Cancer / Brain Neoplasm / Glioblastoma Multiforme (GBM) / Glioma / High Grade Glioma: Glioblastoma (GBM)1
3WithdrawnTreatmentProstate Cancer1
2CompletedTreatmentEpithelial Ovarian Cancer2
2CompletedTreatmentHigh Grade Glioma: Glioblastoma (GBM)1
2RecruitingPreventionMalaria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at November 18, 2007 18:25 / Updated at June 12, 2020 16:52